Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating Activities | ||
| Net income | $55,932 | $35,733 |
| Adjustments to reconcile net income to net cash provided by operating activities | ||
| Depreciation | 1,522 | 1,410 |
| Accretion on marketable securities | (576) | (453) |
| Amortization of operating lease right-of-use assets | 204 | 224 |
| Stock-based compensation expense, net | 13,609 | 13,478 |
| Realized gain on investments | (529) | (1,502) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s D&A?
- Krystal Biotech, Inc. (KRYS) reported D&A of $1.52M in Q1 2026.
- How has Krystal Biotech, Inc.'s D&A changed year-over-year?
- Krystal Biotech, Inc.'s D&A increased by 7.9% year-over-year, from $1.41M to $1.52M.
- What is the long-term trend for Krystal Biotech, Inc.'s D&A?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s D&A has grown at a 19.6% compound annual growth rate (CAGR), from $2.77M to $5.67M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Krystal Biotech, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude